Acesion Pharma

About Acesion Pharma

Acesion Pharma is a Danish biotech company founded in 2011 as a spin-out from Neurosearch and the University of Copenhagen. The company focuses on pioneering first-in-class drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia, through the inhibition of the SK ion channel.

Products & Services

AP30663:A first-in-class SK channel inhibition compound for the treatment of atrial fibrillation, with proof of mechanism achieved in clinical results.

AP31969:A novel therapy for atrial fibrillation, with positive pre-clinical data reported.

Specialties

SK ion channel inhibition Atrial Fibrillation treatment First-in-class drug development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 45000000 MR: - FA: €45M FAN: 45000000	D: 2023-09-26 FD: 2023-09-26	4 investors

Series B Latest

2023-09-26

$45.0M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Peter R. Kowey

Professor of Medicine and Clinical Pharmacology

A

A. John Camm

British Heart Foundation Emeritus Professor of Clinical Cardiology at St. George's University of London

J

Jeremy Ruskin

Professor of Medicine

A

Anthony Damato

Father of Modern Clinical Cardiac Electrophysiology

E

Edgar Haber

Doctor

J

James A. Reiffel

Professor Emeritus of Medicine and Special Lecturer, Columbia University Vagelos College of Physicians and Surgeons; and, Attending Physician [Emeritus] at Presbyterian Hospital in New York City; Department of Medicine, Division of Cardiology, Section of Electrophysiology

View 16 more team members with Pro

Unlock Full Team Directory

Recent News

Acesion Pharma Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised